SLE patients showed a decrease in olfactory ... Past research in mice has shown that injection of antibodies linked to NPSLE manifestations induced olfactory deficit and that these antibodies ...

when there is evidence for antibody-mediated destruction of red blood cells and/or platelets intravenous immunoglobulin tends to be very efficacious; and when the patient with severe SLE also has ...

They assessed the diagnostic value of antineuronal antibody levels in the serum and cerebrospinal fluid of 38 SLE patients with and 29 without CNS involvement, in control patients (36 with non-SLE ...

Systemic Lupus Erythematosus (SLE)—lupus for short—is a chronic, painful and debilitating disease in which the antibodies produced by the immune system mistakenly attack the body's own tissues.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off ...

Lupus nephritis affects 1.7 million people worldwide; up to one-third of people on current treatments will progress to end-stage kidney disease within 10 years2-5 ...